Current stock page

Stock Analysis

AnaptysBio, Inc. (ANAB) Stock Analysis

AnaptysBio, Inc. (ANAB) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ANAB Stock Analysis Summary

AnaptysBio, Inc. (ANAB) currently has an AIQ Score of 56/100, indicating a neutral setup. Value is the strongest factor at 74/100. Momentum is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ANAB at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$46.25
AIQ Score56/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.62B
P/E Ratio (TTM)7.27
Forward P/E—
EPS (Q3 FY2026)$0.13
Revenue (Q3 FY2026)$30.27M
Dividend Yield (TTM)0.00%
Beta1.11
Volume499.64K
52-week range$32.90-$73.30
RSI 1442.73
50-Day SMA$49.79
200-Day SMA$56.50
Analyst Price Target$81.00
Next EarningsMar 2, 2027
As of Nov 13, 2026 · Market close

ANABAnaptysBio, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$46.25−$1.52 (−3.18%)

Latest quote

  • Momentum
    36
  • Value
    74
  • Quality
    72
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ANAB Stock Analysis Summary

AnaptysBio, Inc. (ANAB) currently has an AIQ Score of 56/100, indicating a neutral setup. Value is the strongest factor at 74/100. Momentum is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, ANAB has AIQ Score of 56/100 with Value base of 74/100 and fading Momentum at 36/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (74/100) leads while Momentum (36/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -3.18% stock move · ANAB classified in Biotechnology.

Current Evidence

NeutralANAB is in a neutral AIQ regime; Value is the strongest visible factor at 74/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ANAB Bullish or Bearish Right Now?

ANAB currently has a neutral overall setup. Value is the strongest factor at 74/100, while Momentum is weakest at 36/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 72/100.
  • - Analyst target implies +75.14% upside from the latest quote.
Bear Case
  • - Momentum is weak at 36/100.
  • - Risk Resilience is weak at 46/100.
  • - Price is -18.14% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (33 vs 4).

Current Consensus

ANAB's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 9 neutral, and 33 sell votes. ANAB's 14-day RSI is 42.73, which places the stock in a weaker momentum range. ANAB's beta is 1.11, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in ANAB?

The largest recent change in ANAB is Value moving down by 3.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-1.0
Momentum
+0.0
Quality
+0.0
Risk
-1.0

What Would Change the ANAB Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ANAB Decision Framework

Public evidence layers, setup checks, and risk context for AnaptysBio, Inc..

AnaptysBio, Inc. (ANAB) Stock Analysis

AnaptysBio, Inc. has an AIQ Score of 56/100 in a Neutral regime. Value is strongest at 74/100. Beta is 1.11, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextANAB is in a Neutral AIQ regime with score 56/100.
Signal ConflictThe primary conflict is that value leads at 74/100 while momentum lags at 36/100.
Factor EvidenceMomentum 36/100 · Value 74/100 · Quality 72/100 · Risk 46/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 74/100.

TimingFail

Momentum is 36/100 and RSI (14) is 42.7.

Regime fitWait

ANAB is in a Neutral regime at 56/100.

Risk controlFail

Risk factor is 46/100 with beta 1.11 and annual volatility 64.84%.

ConflictWait

Current conflict: value leads at 74/100 while momentum lags at 36/100.

AIQ Score
56/100
Price
$46.25
Beta
1.11
RSI (14)
42.7

ANAB Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ANAB Fundamentals

ANAB valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$30.27M
Net income
$3.88M
Free cash flow
-$9.54M
View full ANAB fundamental analysis

ANAB Technical Analysis

ANAB technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
42.73
Price vs SMA-50
-7.11%
View full ANAB technical analysis

ANAB Stock Catalysts

Track ANAB earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 2, 2027
Analyst target
$81.00
News items
4
View ANAB earnings and stock catalysts

ANAB Dividend Analysis

ANAB dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ANAB dividend history and analysis

ANAB Financial Data

ANAB revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$30.27M
EPS
$0.13
Periods
8
View ANAB financials

ANAB Risk Analysis

ANAB volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.11
Risk score
46/100
1Y volatility
64.84%
View ANAB risk analysis

ANAB Stock News

ANAB stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read ANAB stock news

ANAB vs Biotechnology Peers

Current peer cohort: ANAB · ARGX · ARQT · ASND · AUPH. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ANAB
Current stock
56/10074/10036/10046/1000.7864.84%Current
ARGX
argenx SE
74/10070/10074/10070/1000.2837.87%ANAB vs ARGX
ARQT
Arcutis Biotherapeutics, Inc.
69/10065/10076/10046/1000.5956.50%ANAB vs ARQT
ASND
Ascendis Pharma A/S
72/10066/10075/10072/1000.8438.55%ANAB vs ASND
AUPH
Aurinia Pharmaceuticals Inc.
75/10084/10073/10068/1000.1635.52%ANAB vs AUPH
Pairwise Compare links: ARGX · ARQT · ASND · AUPHANAB vs ARGXANAB vs ARQTANAB vs ASNDANAB vs AUPHCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ANAB stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ANAB: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
7.27
As of Nov 13, 2026
Revenue growth
-60.33%
Gross margin
143.68%
Current debt / equity
0.6
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$30.27M
Quarter net income
$3.88M
Quarter free cash flow
-$9.54M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
42.73
MACD
-0.59

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
46/100
Beta
1.11
Annual volatility
64.84%
Max drawdown
-35.30%

ANAB Stock FAQ

What is ANAB stock price today?

AnaptysBio, Inc.'s current stock price is $46.25. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ANAB bullish or bearish right now?

ANAB's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ANAB's market cap?

ANAB's market cap is $1.62B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ANAB's current P/E ratio?

ANAB's current P/E ratio is 7.27 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ANAB's RSI?

ANAB's 14-day RSI is 42.73 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ANAB above its 50-day and 200-day moving averages?

ANAB is -7.11% from its 50-day SMA and -18.14% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ANAB's next earnings date?

ANAB's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ANAB pay a dividend?

ANAB's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.